BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to identify the role of BCR-ABL1 transcript level as a predictor for post-transplant relapse and outcome in patients who underwent allogeneic stem cell transplantation (SCT) for chronic phase (CP) chronic myeloid leukemia (CML). Methods: Of 101 patients receiving allograft in CML CP, 85 had available quantitative reverse transcriptase polymerase chain reaction data at post-transplant 3 months. These patients were divided into two groups according to molecular response (MR4.5), defined as a BCR-ABL1 transcript level ≤ 0.0032% on the international scale, at 3 months based on receiver operating characteristic curve analysis of relapse. Results: The 4-year overall survival and event-free survival (EFS) were 80.6% and 57.3%, respectively, and the cumulative incidence of relapse at 4 years was 29.6% after a median follow-up of 126.4 months. We performed multivariate analyses including potential variables to evaluate the early predictive role of MR4.5 at 3 months and found that MR4.5 at 3 months was associated with a higher EFS (p = 0.028) and showed a trend for a lower relapse rate (p = 0.089). Conclusions: our results imply that frequent molecular monitoring and immune suppressive therapy modulation are required for patients without reduction of BCR-ABL1 transcripts to this level after SCT.
Abstract
Background/Aims: The aim of this study was to identify the role of BCR-ABL1 transcript level as a predictor for post-transplant relapse and outcome in patients who underwent allogeneic stem cell transplantation (SCT) for chronic phase (CP) chronic myeloid leukemia (CML). Methods: Of 101 patients receiving allograft in CML CP, 85 had available quantitative reverse transcriptase polymerase chain reaction data at post-transplant 3 months. These patients were divided into two groups according to molecular response (MR4.5), defined as a BCR-ABL1 transcript level ≤ 0.0032% on the international scale, at 3 months based on receiver operating characteristic curve analysis of relapse. Results: The 4-year overall survival and event-free survival (EFS) were 80.6% and 57.3%, respectively, and the cumulative incidence of relapse at 4 years was 29.6% after a median follow-up of 126.4 months. We performed multivariate analyses including potential variables to evaluate the early predictive role of MR4.5 at 3 months and found that MR4.5 at 3 months was associated with a higher EFS (p = 0.028) and showed a trend for a lower relapse rate (p = 0.089). Conclusions: our results imply that frequent molecular monitoring and immune suppressive therapy modulation are required for patients without reduction of BCR-ABL1 transcripts to this level after SCT.
참고문헌 (27)
- Baccarani M, "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013", Blood, 122, pp.872~884 (2013)
- Lee SE, "Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors", Hematology, 19, pp.63~72 (2014)
- Oyekunle A, "Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy", Ann Hematol, 92, pp.487~496 (2013)
- Khoury HJ, "Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis", Bone Marrow Transplant, 47, pp.810~816 (2012)
- Kantarjian HM, "Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia", Blood, 100, pp.1590~1595 (2002)
- Wright MP, "Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation", Biol Blood Marrow Transplant, 16, pp.639~646 (2010)
- Olavarria E, "Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia", Blood, 97, pp.1560~1565 (2001)
- Asnafi V, "Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia", Leukemia, 20, pp.793~799 (2006)
- Kaeda J, "Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy", Blood, 107, pp.4171~4176 (2006)
- Arpinati M, "Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia", Biol Blood Marrow Transplant, 19, pp.735~740 (2013)
- Cross NC, "Standardized definitions of molecular response in chronic myeloid leukemia", Leukemia, 26, pp.2172~2175 (2012)
- Lee SE, "Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib", Am J Hematol, 88, pp.449~454 (2013)
- Przepiorka D, "Consensus conference on acute GVHD grading", Bone Marrow Transplant, 15, pp.825~828 (1995)
- Lee SJ, "Chronic graft-versushost disease", Biol Blood Marrow Transplant, 9, pp.215~233 (2003)
- Cullis JO, "Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation", Blood, 79, pp.1379~1381 (1992)
- van Rhee F, "Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia", Bone Marrow Transplant, 14, pp.609~612 (1994)
- Inamoto Y, "Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation", Blood, 118, pp.456~463 (2011)
- Mackinnon S, "Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease", Blood, 86, pp.1261~1268 (1995)
- Dazzi F, "Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia", Blood, 95, pp.67~71 (2000)
- Kolb HJ, "Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients", Blood, 86, pp.2041~2050 (1995)
- Collins RH Jr, "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J Clin Oncol, 15, pp.433~444 (1997)
- Savani BN, "Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation", Bone Marrow Transplant, 36, pp.1009~1015 (2005)
- Olavarria E, "Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation", Blood, 99, pp.3861~3862 (2002)
- Wassmann B, "Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation", Bone Marrow Transplant, 28, pp.721~724 (2001)
- Kim YJ, "Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse", Biol Blood Marrow Transplant, 10, pp.718~725 (2004)
- Weiden PL, "Antileukemic effect of chronic graft-versus-host disease:contribution to improved survival after allogeneic marrow transplantation", N Engl J Med, 304, pp.1529~1533 (1981)
- Baron F, "Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning", J Clin Oncol, 23, pp.1993~2003 (2005)